Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 10/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | PADI6 | Q6TGC4 | 1/20 | 0.56 |
| ▸ | PADI4 | Q9UM07 | 6/20 | 0.55 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PADI2 | Q9Y2J8 | 3/20 | 0.50 |
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10060141 | 0.95 | KDM1A (0.57) | KDM1AMAOAPADI6PADI4KDM1B | |
| SCHEMBL10060566 | 0.91 | PADI6 (0.69) | KDM1AMAOAPADI6PADI4KDM1B | |
| SCHEMBL10060142 | 0.91 | KDM1A (0.58) | KDM1AMAOAPADI6PADI4KDM1B | |
| SCHEMBL10060137 | 0.85 | PADI4 (0.54) | KDM1AMAOAPADI6PADI4KDM1B | |
| SCHEMBL10026327 | 0.82 | PADI4 (0.72) | KDM1AMAOAPADI6PADI4KDM1B | |
| SCHEMBL10060143 | 0.82 | PADI6 (0.62) | KDM1AMAOAPADI6PADI4KDM1B | |
| SCHEMBL10060144 | 0.80 | HDAC1 (0.67) | PADI6PADI4L3MBTL1PADI2 | |
| SCHEMBL10060236 | 0.80 | HDAC4 (0.51) | PADI6PADI4PADI2 | |
| SCHEMBL3576509 | 0.79 | ADAMTS5 (0.62) | KDM1AMAOAL3MBTL1CTSBCTSS | |
| SCHEMBL10060140 | 0.79 | MCHR1 (0.56) | PADI6PADI4PADI2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969333-B2 | Therapeutic compositions and methods | THE PENN STATE RESEARCH FOUNDATION (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140288059-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE PENN STATE RESEARCH FOUNDATION (US) | 2014-09-25 | — | — | US | disclosed |
| US-20120108562-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288059-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | PADI4, PADI2, PADI3 | KDM1A 190/4885MAOA 1507/4885PADI6 5/4885 |
| US-20120108562-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | PADI4, PADI2, PADI3 | KDM1A 190/4885MAOA 1507/4885PADI6 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.